Treatment
Ublituximab clinical trials
We’re tracking 14 recruiting studies that include Ublituximab, each written for real people, not researchers, below.
Recruiting studies
- NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT07680946RecruitingPhase 2
Testing ublituximab for treatment-resistant schizophrenia
This trial tests an experimental drug, ublituximab, to see if it helps people with schizophrenia that hasn't gotten better with standard treatments. It may offer a new option for those who still have significant symptoms despite current therapy.
Little Rock, ArkansasAges 18–60 - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Birmingham, AlabamaAges 18–65 - NCT07673744RecruitingPhase 2
Maintenance treatment for myasthenia gravis after efgartigimod
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
Colorado Springs, ColoradoAges 18 years+ - NCT07503873RecruitingPhase 2
Study of ublituximab injection for multiple sclerosis
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
BihaćAges 18–65 - NCT07220252RecruitingPhase 2/Phase 3
Ublituximab for children with relapsing multiple sclerosis
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
GdanskAges 10–17 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT07225361RecruitingPhase 4
Ublituximab for early relapsing multiple sclerosis
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Chicago, IllinoisAges 18–70 - NCT07389590RecruitingPhase 4
Switching MS drugs for wearing-off symptoms
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
Baltimore, MarylandAges 18–65 - NCT06143514Recruiting
Study of BRIUMVI in breast milk
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
San Francisco, CaliforniaAges 18 years+ - NCT06433752Recruiting
Study of BRIUMVI for relapsing multiple sclerosis
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
Birmingham, AlabamaAges 18 years+ - NCT06433765Recruiting
BRIUMVI and pregnancy safety in multiple sclerosis
This study looks at the effects of the MS medication BRIUMVI on pregnancy and baby health. It compares women who took BRIUMVI during pregnancy to those who did not.
Wilmington, North CarolinaAges 15–50
What Ublituximab is being studied for
Conditions with recruiting Ublituximab studies.
Common questions
- Are there clinical trials studying Ublituximab?
- Yes. Clin2 currently lists 14 recruiting studies that include Ublituximab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ublituximab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ublituximab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ublituximab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.